-
Cancer investigation · Jun 2013
Multicenter StudySorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
- John D Hainsworth, David M Waterhouse, William C Penley, Dianna L Shipley, Dana S Thompson, Charles D Webb, and F Anthony Greco.
- Sarah Cannon Research Institute, Nashville, TN 37203, USA. jhainsworth@tnonc.com
- Cancer Invest. 2013 Jun 1; 31 (5): 323-9.
PurposeTo evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC).MethodsPatients with advanced RCC and ≤ 1 previous targeted therapy were treated.ResultsMaximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common.ConclusionsFifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..